Technical Analysis for IMGN - ImmunoGen, Inc.

Grade Last Price % Change Price Change
grade F 2.41 -6.23% -0.16
IMGN closed down 6.23 percent on Friday, March 22, 2019, on 84 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical IMGN trend table...

Date Alert Name Type % Chg
Mar 22 New 52 Week Closing Low Bearish 0.00%
Mar 22 1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Mar 22 180 Bearish Setup Bearish Swing Setup 0.00%
Mar 22 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Mar 22 Outside Day Range Expansion 0.00%
Mar 22 Wide Bands Range Expansion 0.00%
Mar 21 MACD Bullish Signal Line Cross Bullish -6.23%
Mar 21 Outside Day Range Expansion -6.23%
Mar 21 Wide Bands Range Expansion -6.23%
Mar 21 Oversold Stochastic Weakness -6.23%

Older signals for IMGN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
ImmunoGen, Inc. engages in the development of antibody-based anticancer therapeutics. The company develops its products using its targeted antibody payload (TAP) technology. Its product candidates include Trastuzumab emtansine, a Phase III clinical trial product for HER2+ metastatic breast cancer; lorvotuzumab mertansine, which is in Phase II clinical trial for the treatment of diagnosed metastatic small-cell lung cancer, as well as in a Phase I clinical trial for the treatment of multiple myeloma; IMGN853, a Phase I clinical trial product that targets over-expressed folate receptor 1 in ovarian cancer and other types of solid tumors, including non-small cell lung cancer; and IMGN529, a product in Phase I clinical trial for treatment of non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia. The company's compounds in earlier-stage of development comprise SAR3419, a Phase II clinical trial product to treat CD19-expressing B-cell malignancies, such as NHL and B-cell acute lymphoblastic leukemia; BT-062, a Phase I product, which targets CD138 antigen found on multiple myeloma and various solid tumors; SAR650984, a Phase I clinical trial product for CD38-targeting hematological malignancies; SAR566658, a Phase I clinical trial product for DS6-expressing solid tumors; BAY 94-9343, a Phase I clinical trial product for mesothelin-expressing solid tumors; and Amgen 1 and Amgen 2, which are phase I clinical trial compounds. It has collaborations with Amgen Inc.; Bayer HealthCare; Biotest AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; Genentech, Inc; Sanofi; and Hoffman-La Roche Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Biotechnology Clinical Medicine Drugs Solid Tumors Monoclonal Antibodies Non Small Cell Lung Cancer Ovarian Cancer Lymphoma Multiple Myeloma Chronic Lymphocytic Leukemia Antibody Drug Conjugates Clinical Trial Product Metastatic Breast Cancer Amgen NHL Immunogen Its Its Products Her2 Metastatic Small Cell Lung Cancer
Is IMGN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 13.41
52 Week Low 2.27
Average Volume 3,871,061
200-Day Moving Average 7.1509
50-Day Moving Average 4.4064
20-Day Moving Average 3.1355
10-Day Moving Average 2.6
Average True Range 0.3026
ADX 39.14
+DI 13.4899
-DI 37.9865
Chandelier Exit (Long, 3 ATRs ) 5.2222
Chandelier Exit (Short, 3 ATRs ) 3.1778
Upper Bollinger Band 5.3222
Lower Bollinger Band 0.9488
Percent B (%b) 0.33
BandWidth 139.480147
MACD Line -0.6284
MACD Signal Line -0.6415
MACD Histogram 0.0131
Fundamentals Value
Market Cap 215.93 Million
Num Shares 89.6 Million
EPS -1.22
Price-to-Earnings (P/E) Ratio -1.98
Price-to-Sales 5.58
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.74
Resistance 3 (R3) 2.77 2.70 2.69
Resistance 2 (R2) 2.70 2.61 2.68 2.67
Resistance 1 (R1) 2.55 2.56 2.52 2.52 2.65
Pivot Point 2.48 2.48 2.46 2.46 2.48
Support 1 (S1) 2.33 2.39 2.30 2.30 2.17
Support 2 (S2) 2.26 2.34 2.24 2.15
Support 3 (S3) 2.11 2.26 2.14
Support 4 (S4) 2.08